NEW YORK — The OS benefit observed with nivolumab compared with investigator’s choice of single-agent chemotherapy for patients with recurrent or metastatic head and neck squamous cell carcinoma who previously received platinum therapy occurred regardless of patient age, according to a post hoc analysis of the CheckMate 141 trial presented at Chemotherapy Foundation Symposium.
In addition, objective response rates were higher with nivolumab (Opdivo, Bristol-Myers Squibb) among patients aged younger than 65 years, as well as those aged 65 years or older.
There is no commercial support for this activity.
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2018 Healio All Rights Reserved.